Cargando…

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study

The predictive effect of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) treatment is still highly discussed. The primary objective of our study was to investigate a possible prognostic/predictive value of ctDNA under regorafenib treatment. This prospective multicenter translational biomark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unseld, Matthias, Belic, Jelena, Pierer, Kerstin, Zhou, Qing, Moser, Tina, Bauer, Raimund, Piringer, Gudrun, Gerger, Armin, Siebenhüner, Alexander, Speicher, Michael, Heitzer, Ellen, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894541/ https://www.ncbi.nlm.nih.gov/pubmed/32949150 http://dx.doi.org/10.1002/ijc.33303

Ejemplares similares

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Correction: Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2019)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
por: Chiesa, Silvia, et al.
Publicado: (2022)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
por: Zhao, Bin, et al.
Publicado: (2017)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
por: Strasma, Anna, et al.
Publicado: (2021)

The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib
por: Zhuo, Jianyong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bo4qq96qr0p7e3mb2dtr9agp3r